Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
9
×
cancer immunotherapy
9
×
detroit blog main
detroit top stories
indiana blog main
9
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
9
×
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
startups
clinical trials
deals
eli lilly
fda
investing
pfizer
biogen
abbvie
alzheimer's disease
bristol-myers squibb
What
roundup
9
×
bio
drug
companies
alzheimer’s
annual
attention
biotech
days
growing
ipo
life
nash
new
news
pharmaceutical
price
prices
science
typically
week
acquisitions
ahead
alliance
ambien
american
announced
approval
approved
arena’s
asco
assessed
attendees
bails
biogen’s
biopharmaceutical
bounty
brand
bridgebio
bristol
Language
unset
Current search:
roundup
×
cancer
×
" indiana blog main "
×
photo
×
" texas blog main "
×
" cancer immunotherapy "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More